Llwytho...

Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans

This study examines PCSK9i cost-sharing requirements for Medicare Part D plans nationwide, which insure 41 million beneficiaries.

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:JAMA Cardiol
Prif Awduron: Kazi, Dhruv S., Lu, Christine Y., Lin, Grace A., DeJong, Colette, Dudley, R. Adams, Chen, Randi, Tseng, Chien-Wen
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Medical Association 2017
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815006/
https://ncbi.nlm.nih.gov/pubmed/28903137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3051
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!